Status: Not yet recruiting
A Study of HL40626S Tablets in Healthy Adults
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.
Participants needed: 64
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: HighsLab Therapeutics Inc.Updated: Aug 3, 2026Locations: 1
Eligibility criteria
Capable of understanding the written informed consent document; willingly provid... [+6]
Clinically significant abnormal medical history, such as gastrointestinal, cardi... [+21]